-DOCSTART- -X- O
In -X- _ O
critically -X- _ B-Patient
ill -X- _ I-Patient
patients -X- _ I-Patient
, -X- _ O
organ -X- _ O
dysfunctions -X- _ O
are -X- _ O
routinely -X- _ O
assessed -X- _ O
, -X- _ O
monitored -X- _ O
, -X- _ O
and -X- _ O
treated. -X- _ O
Mounting -X- _ O
data -X- _ O
show -X- _ O
that -X- _ O
substantial -X- _ O
critical -X- _ O
illness-induced -X- _ O
changes -X- _ O
in -X- _ O
the -X- _ O
immune -X- _ O
system -X- _ O
can -X- _ O
be -X- _ O
observed -X- _ O
in -X- _ O
most -X- _ O
ICU -X- _ B-Patient
patients -X- _ I-Patient
and -X- _ O
that -X- _ O
not -X- _ O
only -X- _ O
“hyper-inflammation” -X- _ O
but -X- _ O
also -X- _ O
persistence -X- _ O
of -X- _ O
an -X- _ O
anti-inflammatory -X- _ O
phenotype -X- _ O
( -X- _ O
as -X- _ O
in -X- _ O
sepsis-associated -X- _ O
immunosuppression -X- _ O
) -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
increased -X- _ O
morbidity -X- _ O
and -X- _ O
mortality. -X- _ O
Despite -X- _ O
common -X- _ O
perception -X- _ O
, -X- _ O
changes -X- _ O
in -X- _ O
functional -X- _ O
immunity -X- _ O
can -X- _ O
not -X- _ O
be -X- _ O
adequately -X- _ O
assessed -X- _ O
by -X- _ O
routine -X- _ O
inflammatory -X- _ O
biomarkers -X- _ O
such -X- _ O
as -X- _ O
C-reactive -X- _ O
protein -X- _ O
, -X- _ O
procalcitonin -X- _ O
, -X- _ O
or -X- _ O
numerical -X- _ O
analysis -X- _ O
of -X- _ O
leukocyte -X- _ O
( -X- _ O
sub -X- _ O
) -X- _ O
-counts. -X- _ O
Cytokines -X- _ O
appear -X- _ O
also -X- _ O
not -X- _ O
suited -X- _ O
due -X- _ O
to -X- _ O
their -X- _ O
short -X- _ O
half-life -X- _ O
and -X- _ O
pleiotropy -X- _ O
, -X- _ O
their -X- _ O
unexclusive -X- _ O
origin -X- _ O
from -X- _ O
immune -X- _ O
cells -X- _ O
, -X- _ O
and -X- _ O
their -X- _ O
potential -X- _ O
to -X- _ O
undergo -X- _ O
antagonization -X- _ O
by -X- _ O
circulating -X- _ O
inactivating -X- _ O
molecules. -X- _ O
Thus -X- _ O
, -X- _ O
beyond -X- _ O
leukocyte -X- _ O
quantification -X- _ O
and -X- _ O
use -X- _ O
of -X- _ O
routine -X- _ O
biomarkers -X- _ O
, -X- _ O
direct -X- _ O
assessment -X- _ B-Intervention
of -X- _ I-Intervention
immune -X- _ I-Intervention
cell -X- _ I-Intervention
function -X- _ I-Intervention
seems -X- _ O
required -X- _ O
to -X- _ O
characterize -X- _ O
the -X- _ O
immune -X- _ O
systems’ -X- _ O
status. -X- _ O
This -X- _ O
may -X- _ O
include -X- _ O
determination -X- _ O
of -X- _ O
, -X- _ O
e.g. -X- _ O
, -X- _ O
ex -X- _ O
vivo -X- _ O
cellular -X- _ O
cytokine -X- _ O
release -X- _ O
, -X- _ O
phagocytosis -X- _ O
activity -X- _ O
, -X- _ O
and -X- _ O
/ -X- _ O
or -X- _ O
antigen-presenting -X- _ O
capacity. -X- _ O
In -X- _ O
this -X- _ O
regard -X- _ O
, -X- _ O
standardized -X- _ O
flow-cytometric -X- _ O
assessment -X- _ B-Intervention
of -X- _ I-Intervention
the -X- _ I-Intervention
major -X- _ I-Intervention
histocompatibility-II -X- _ I-Intervention
complex -X- _ I-Intervention
human -X- _ I-Intervention
leukocyte -X- _ I-Intervention
antigen -X- _ I-Intervention
( -X- _ I-Intervention
-D -X- _ I-Intervention
related -X- _ I-Intervention
) -X- _ I-Intervention
( -X- _ I-Intervention
HLA-DR -X- _ I-Intervention
) -X- _ I-Intervention
has -X- _ O
gained -X- _ O
particular -X- _ O
interest. -X- _ O
Monocytic -X- _ O
HLA-DR -X- _ O
( -X- _ O
mHLA-DR -X- _ O
) -X- _ O
controls -X- _ O
the -X- _ O
interplay -X- _ O
between -X- _ O
innate -X- _ O
and -X- _ O
adaptive -X- _ O
immunity -X- _ O
and -X- _ O
may -X- _ O
serve -X- _ O
as -X- _ O
a -X- _ O
“global” -X- _ O
biomarker -X- _ O
of -X- _ O
injury-associated -X- _ O
immunosuppression -X- _ O
, -X- _ O
and -X- _ O
its -X- _ O
decreased -X- _ O
expression -X- _ O
is -X- _ O
associated -X- _ O
with -X- _ O
adverse -X- _ O
clinical -X- _ O
outcomes -X- _ O
( -X- _ O
e.g. -X- _ O
, -X- _ O
secondary -X- _ O
infection -X- _ O
risk -X- _ O
, -X- _ O
mortality -X- _ O
) -X- _ O
. -X- _ O
Importantly -X- _ O
, -X- _ O
recent -X- _ O
data -X- _ O
demonstrate -X- _ O
that -X- _ O
injury-associated -X- _ O
immunosuppression -X- _ O
can -X- _ O
be -X- _ O
reversed—opening -X- _ O
up -X- _ O
new -X- _ O
therapeutic -X- _ O
avenues -X- _ O
in -X- _ O
affected -X- _ O
patients. -X- _ O
Here -X- _ O
we -X- _ O
discuss -X- _ O
the -X- _ O
potential -X- _ O
scientific -X- _ O
and -X- _ O
clinical -X- _ O
value -X- _ O
of -X- _ O
assessment -X- _ B-Intervention
of -X- _ I-Intervention
functional -X- _ I-Intervention
immunity -X- _ I-Intervention
with -X- _ O
a -X- _ O
focus -X- _ O
on -X- _ O
monocytes -X- _ O
/ -X- _ O
macrophages -X- _ O
and -X- _ O
review -X- _ O
the -X- _ O
current -X- _ O
state -X- _ O
of -X- _ O
knowledge -X- _ O
and -X- _ O
potential -X- _ O
perspectives -X- _ O
for -X- _ O
affected -X- _ O
critically -X- _ B-Patient
ill -X- _ I-Patient
patients -X- _ I-Patient
. -X- _ O

